Protara Therapeutics, Inc. Common Stock (TARA)
Protara Therapeutics, Inc. (TARA) is a biotechnology company focused on developing innovative therapies for cancer and rare diseases. It is dedicated to advancing treatments through its pipeline of novel drug candidates, with an emphasis on targeted and personalized medicine approaches.
Company News
Protara Therapeutics reported a Q2 2025 net loss of $15.0 million, with no revenue but continued progress in clinical trials for TARA-002 and IV Choline Chloride. The company maintains $145.6 million in cash reserves, projecting operational funding into mid-2027.
Protara Therapeutics announced positive interim results from its ongoing Phase 2 ADVANCED-2 trial of TARA-002, its investigational cell-based therapy, in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The results showed high complete response rates and a favorable safety profile.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Susquehanna raised the price target for Occidental Petroleum Corporation (NYSE:OXY) from $70 to $81. Susquehanna analyst Biju Perincheril maintained a Positiv...
Protara Therapeutics (TARA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.